Your session is about to expire
← Back to Search
Methylphenidate Hydrochloride Controlled-Release Capsules for Agoraphobia
Study Summary
Other psychiatric disorders, including anxiety, often co-occur with adult ADHD; with 85% of ADHD patients having at least one other psychiatric condition. The presence of a co-occurring anxiety disorder has been associated with additive clinical effects, leading to more global impairment, poorer outcome, greater resistance to treatment and increased costs of illness. Stimulants are effective first-line treatments for adult ADHD patients, however the literature has mostly examined these treatments in pure ADHD populations (i.e. without other psychiatric disorders). Thus, there is little information to guide physicians in making treatment decisions for patients with ADHD and a co-occurring condition. This trial aims to evaluate the efficacy and safety of methylphenidate hydrochloride controlled release capsules (Foquest) in treating adults aged 18-65 years with DSM-5 ADHD with and without a co-occurring anxiety disorder.The study uses a 14-week, randomized, placebo-controlled, cross-over design.
- Agoraphobia
- Attention Deficit Hyperactivity Disorder (ADHD)
- Panic Disorder
- Generalized Anxiety Disorder
- Social Anxiety Disorder
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2020 Phase 4 trial • 267 Patients • NCT02039908Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Who else is applying?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
What state do they live in?
How many prior treatments have patients received?
Share this study with friends
Copy Link
Messenger